Aviso Financial’s PharmaCyte Biotech PMCB Stock Holding History

Aviso Financial’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12	Closed	-$8	–	372
2025 Q4	$8	Buy	+12	New	+$11	﹤0.01%	344

Other funds holding PMCB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Aviso Financial's PMCB Position: Q1 2026 in Review

Aviso Financial sold out of PharmaCyte Biotech (PMCB) in Q1 2026, closing a stake of 12 shares — an estimated $8 sold.

Aviso Financial first reported a position in PMCB in Q4 2025 and held it in 1 quarter. The position peaked at $8 in Q4 2025. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

Aviso Financial reported no remaining PharmaCyte Biotech position as of Q1 2026 after selling out during the quarter.
Aviso Financial sold 12 PharmaCyte Biotech shares in Q1 2026, an estimated $8.
Aviso Financial first reported a position in PharmaCyte Biotech in Q4 2025 and held it in 1 quarter.
Aviso Financial's PharmaCyte Biotech position peaked at $8 in Q4 2025.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Aviso Financial's 13F filing for Q1 2026, filed 14 May 2026.